LogoFDA 510(k) Search
Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K193532
    Device Name
    LIAISON Anti-HAV Assay
    Manufacturer
    DiaSorin Inc.
    Date Cleared
    2020-03-02

    (73 days)

    Product Code
    LOL,JJE
    Regulation Number
    866.3310
    Type
    Traditional
    Panel
    Microbiology
    Reference & Predicate Devices
    K082049
    Why did this record match?
    Reference Devices :

    K082049

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The LIAISON® Anti-HAV assay is an in vitro chemiluminescent immunoassay intended for the qualitative detection of total antibodies to hepatitis A (anti-HAV) in human serum and sodium heparin plasma samples using the LIAISON® Analyzer family. The assay is indicated as an aid in the laboratory diagnosis of current or previous HAV infections in conjunction with other serological and clinical information and to determine the presponse to HAV in vaccine recipients.

    The assay is not intended for screening blood or solid or soft tissue donors.

    Device Description

    The method for qualitative determination of anti-HAV is a competitive sandwich chemiluminescence immunoassay (CLIA) based on neutralization. The assay uses magnetic particles (solid phase) coated with IqG antibodies to HAV (mouse monoclonal), and a mouse monoclonal anti-HAV antibody conjugate linked to an isoluminol derivative (isoluminol-antibody conjuqate). The first incubation step consists of adding the HAV antigen to calibrators, samples or controls, during which anti-HAV present in calibrators, samples or controls binds to a fixed and limited amount of HAV. thus forming an HAV-anti-HAV immune complex. After this step the second incubation follows and it involves addition of magnetic microparticles and conjugate into the cuvette, during which the antibody conjugate and the solid-phase antibody compete with anti-HAV present in the specimen for HAV. This allows the conjugate to bind to the solid phase and to form a sandwich. If all HAV added is sequestered in an HAV-anti-HAV immune complex during the first incubation, no sandwich is formed during the second incubation. After the second incubation, the unbound material is removed with a wash cycle. Subsequently, the starter reagents are added and a flash chemiluminescence reaction is thus induced. The light signal, and hence the amount of isoluminol-antibody conjugate, is measured by a photomultiplier as relative light units (RLU) and is inversely indicative of anti-HAV present in calibrators, samples or controls.

    AI/ML Overview

    Here's an analysis of the provided text regarding the DiaSorin Inc. LIAISON® Anti-HAV device, outlining acceptance criteria and study details:

    Acceptance Criteria and Device Performance

    The provided document describes two main performance studies: a Method Comparison study and a Reproducibility study. The "acceptance criteria" are implied by the reported agreement percentages and coefficient of variation (%CV) values, which are generally expected to be high for agreement and low for variation in diagnostic assays.

    Table of Acceptance Criteria and Reported Device Performance

    Performance MetricAcceptance Criteria (Implied)Reported Device Performance
    Method Comparison
    Negative AgreementHigh agreement (e.g., >85-90%) with predicate.97.4% (38/39) 95% Cl: 86.8% to 99.5%
    Positive AgreementHigh agreement (e.g., >85-90%) with predicate.96.7% (58/60) 95% Cl: 88.6% to 99.1%
    Overall AgreementHigh agreement (e.g., >90%) with predicate.97.0% (96/99) 95% Cl: 91.5% to 99.0%
    Reproducibility
    Repeatability (within Day)Low %CV (e.g.,
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1